These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16309337)

  • 1. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
    Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ
    Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
    Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
    Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of price competition in Italian pharmaceutical off-patent market.
    Perna S; Cangini A; Marini R; Guerrizio MA; Da Cas R; Traversa G; Trotta F
    Front Med (Lausanne); 2022; 9():1045374. PubMed ID: 36523775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of patent expiry on drug prices: insights from the Dutch market.
    van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH
    J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457
    [No Abstract]   [Full Text] [Related]  

  • 9. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
    Kelton CM; Chang LV; Kreling DH
    Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors.
    Vandoros S
    Health Econ; 2014 May; 23(5):621-30. PubMed ID: 23696193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Clarke PM; Fitzgerald EM
    Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative analysis of generics markets in five European countries.
    Garattini L; Tediosi F
    Health Policy; 2000 Apr; 51(3):149-62. PubMed ID: 10720685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing generic and branded substitution patterns in the Netherlands using prescription data.
    Pechlivanoglou P; van der Veen WJ; Bos JH; Postma MJ
    BMC Health Serv Res; 2011 Apr; 11():89. PubMed ID: 21524312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prozac. A bitter pill.
    McLean B
    Fortune; 2001 Aug; 144(3):118-22, 126, 130-2. PubMed ID: 11499050
    [No Abstract]   [Full Text] [Related]  

  • 20. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.